Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Cureus ; 16(4): e57957, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38738096

ABSTRACT

Introduction In Japan, in the seventh wave of coronavirus disease 2019 (COVID-19) from July 2022 to September 2022, followed by the eighth wave of COVID-19 from November 2022 to January 2023, nosocomial clusters became more frequent in many healthcare facilities. If a cluster occurs in a hospital, the restrictions on general healthcare and the impact on hospital management, as well as the impact on community healthcare, are enormous. We analyzed the risk factors for COVID-19 cluster infection in hospitalized patients. Methods We retrospectively collected cases of COVID-19 infection among hospitalized patients in the seventh and eighth waves. The occurrence of a COVID-19 patient in a hospitalized patient was defined as one event. Results A total of 40 events were observed in the seventh and eighth waves. There were 17 events that developed into clusters. The following factors showed a significant association with cluster infection in a univariate analysis: "seventh wave," "originated from healthcare worker," and "initial examination according to contact list." The multivariate analysis revealed that "originated from healthcare worker" was independently associated with cluster infection. Conclusion Preventing the development of COVID-19 clusters is very important for nosocomial infection control. Our study suggests that COVID-19 infection in a healthcare worker is a risk factor for the development of a cluster. When healthcare workers are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it is often due to household transmission. Measures against household transmissions are important to prevent infection among healthcare workers.

2.
Intern Med ; 61(17): 2677-2680, 2022 Sep 01.
Article in English | MEDLINE | ID: mdl-35135912

ABSTRACT

A 66-year-old man was admitted to our hospital for gastrointestinal perforation. He had a history of surgery and chemotherapy for colorectal cancer and had a subcutaneously implanted central venous port catheter. After surgery for gastrointestinal tract perforation, he developed an intra-abdominal abscess, which was treated with broad-spectrum antimicrobial agents and improved. Following this improvement, Rhodotorula spp. was detected in a blood culture and at the catheter tip. He was asymptomatic despite having fungemia. His condition improved after the removal of the catheter and the administration of antifungal drugs. Fungemia due to Rhodotorula spp. is rare, and asymptomatic fungemia is even rarer.


Subject(s)
Catheterization, Central Venous , Central Venous Catheters , Fungemia , Rhodotorula , Aged , Antifungal Agents/therapeutic use , Catheterization, Central Venous/adverse effects , Central Venous Catheters/adverse effects , Fungemia/drug therapy , Humans , Male
3.
Nihon Kokyuki Gakkai Zasshi ; 49(7): 506-10, 2011 Jul.
Article in Japanese | MEDLINE | ID: mdl-21842687

ABSTRACT

Although drug-induced interstitial pneumonitis caused by gefitinib is well recognized in Japan, reports of alveolar hemorrhage caused by gefitinib are very rare. We encountered a case of alveolar hemorrhage thought to be caused by gefitinib. A 74-year-old woman with non-small cell lung cancer (adenocarcinoma; cT4NOM0, stage IIIB) had been receiving gefitinib as second-line therapy from January 2009. However, bloody sputum and nasal bleeding were observed 2 weeks after the initiation of gefitinib therapy. Chest radiography and computed tomography revealed ground-glass opacities predominantly in the lower lung fields. Bronchoscopy was performed, and the bronchoalveolar lavage fluid obtained from the right B8 was bloody. Her symptoms and chest ground-glass opacities improved after the withdrawal of gefitinib. Based on these clinical findings, we diagnosed alveolar hemorrhage caused by gefitinib. If chest radiography or computed tomography findings of gefitinib-treated patients show ground-glass opacities, the possibility of not only interstitial pneumonitis, but also alveolar hemorrhage should be considered in the differential diagnosis.


Subject(s)
Antineoplastic Agents/adverse effects , Hemorrhage/chemically induced , Lung Diseases/chemically induced , Pulmonary Alveoli , Quinazolines/adverse effects , Adenocarcinoma/drug therapy , Aged , Carcinoma, Non-Small-Cell Lung/drug therapy , Female , Gefitinib , Humans , Lung Neoplasms/drug therapy
4.
Rinsho Shinkeigaku ; 59(10): 641-645, 2019 Oct 26.
Article in Japanese | MEDLINE | ID: mdl-31564701

ABSTRACT

A 76-year-old Japanese female who was treated with long-term use of prednisolone at 10 mg/day for interstitial pneumonia developed acute right-dominant lower limb paralysis and then upper limb paralysis with herpes zoster eruptions on the right C7-Th1 dermatomes. On admission, right predominant quadriplegia was observed with sensory symptoms; Hughes functional grade was level 4; the hand grip power was right, 0, and left, 7 kg, the deep tendon reflexes were abolished throughout without pathologic reflexes. Twenty days after the onset of the symptoms, the cerebrospinal fluid (CSF) revealed mild increases of lymphocytes (13 cells/µl) and protein content (73 mg/dl). Varicella-zoster virus (VZV) PCR was negative in the CSF, but an enzyme immunoassay for VZV was positive in her serum and CSF, and the high titers were prolonged. Peripheral nerve conduction and F wave studies suggested right-dominant demyelinating polyradiculoneuropathy. A T1-weighted MR contrast image exhibited right-dominant high-intensity lesions on the C7-Th1 spinal roots and similar lesions on the L4-5 spinal roots. We compared with several similar cases from the literature and proposed that VZV itself involves the pathogenesis of the polyradiculoneuritis in immunocompromised hosts.


Subject(s)
Herpes Zoster/complications , Polyradiculoneuropathy/complications , Polyradiculoneuropathy/virology , Varicella Zoster Virus Infection , Acyclovir/administration & dosage , Acyclovir/adverse effects , Aged , Antibodies, Viral/blood , Antibodies, Viral/cerebrospinal fluid , Antiviral Agents/administration & dosage , Antiviral Agents/adverse effects , Biomarkers/blood , Biomarkers/cerebrospinal fluid , Diffusion Magnetic Resonance Imaging , Female , Guillain-Barre Syndrome , Herpes Zoster/drug therapy , Herpesvirus 3, Human/immunology , Humans , Immunocompromised Host , Immunoglobulins, Intravenous/administration & dosage , Oxadiazoles/administration & dosage , Polyradiculoneuropathy/diagnosis , Polyradiculoneuropathy/drug therapy , Quadriplegia/etiology
5.
Intern Med ; 56(2): 203-206, 2017.
Article in English | MEDLINE | ID: mdl-28090053

ABSTRACT

A 39-year-old man treated with dasatinib for chronic myelogenous leukaemia presented to our hospital with haemoptysis, coughing, and dyspnoea. Chest radiography and computed tomography revealed ground-glass opacities and a crazy-paving pattern. Bronchoalveolar lavage was not performed due to serious hypoxemia and bleeding. Significant bleeding from the peripheral bronchi led to a diagnosis of an alveolar haemorrhage. Dasatinib-induced alveolar haemorrhaging was suspected based on the clinical findings. His condition improved immediately after dasatinib withdrawal and initiation of steroid therapy. Reports of alveolar haemorrhaging induced by dasatinib are rare. As such, this is considered an important case.


Subject(s)
Dasatinib/therapeutic use , Hemorrhage/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy , Protein Kinase Inhibitors/therapeutic use , Pulmonary Alveolar Proteinosis/diagnosis , Adult , Cough/etiology , Dasatinib/adverse effects , Diagnosis, Differential , Dyspnea/etiology , Hemorrhage/chemically induced , Hemorrhage/diagnostic imaging , Humans , Male , Protein Kinase Inhibitors/adverse effects , Pulmonary Alveolar Proteinosis/chemically induced , Pulmonary Alveolar Proteinosis/complications , Pulmonary Alveolar Proteinosis/diagnostic imaging , Radiography, Thoracic , Tomography, X-Ray Computed
6.
Respir Investig ; 52(2): 114-20, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24636267

ABSTRACT

BACKGROUND: Nursing and healthcare-associated pneumonia (NHCAP) is a relatively new condition that was recently defined by the Japanese Respiratory Society. Previous reports and guidelines have not thoroughly investigated the adverse prognostic factors and validity of the selection criteria for NHCAP. The purpose of this research was to clarify the adverse prognostic factors of NHCAP and investigate the validity of the selection criteria with respect to patient deaths. METHODS: We retrospectively analyzed 418 patients with pneumonia who were admitted to our hospital between January 2009 and December 2011. RESULTS: We analyzed 215 (51.4%) cases of community-acquired pneumonia (CAP) and 203 (48.6%) cases of NHCAP. NHCAP patients were generally older and had poorer performance status (PS), more complications, and higher levels of mortality than CAP patients. In both groups, the most common causative pathogen was Streptococcus pneumoniae. A multivariate analysis of NHCAP revealed that age ≥ 80 years, oxygen saturation (SpO2) ≤ 90%, and methicillin-resistant Staphylococcus aureus (MRSA) infection to be independent factors associated with mortality. Of the NHCAP selection criteria, a PS ≥ 3 and a hospitalization history within the past 90 days were adverse prognostic factors in the broad community-acquired pneumonia category (CAP+NHCAP), according to a multivariate analysis. Univariate analysis revealed that admission to an extended care facility or nursing home was associated with death. CONCLUSIONS: Our results demonstrated that age ≥ 80 years, SpO2 ≤ 90%, and MRSA infection were adverse prognostic factors for NHCAP patients. Furthermore, we confirmed the validity of the NHCAP selection criteria.


Subject(s)
Community-Acquired Infections/mortality , Cross Infection/mortality , Pneumonia/mortality , Age Factors , Community-Acquired Infections/microbiology , Cross Infection/microbiology , Hospitalization , Methicillin-Resistant Staphylococcus aureus , Oxygen/blood , Pneumonia/microbiology , Prognosis , Retrospective Studies , Staphylococcal Infections , Streptococcus pneumoniae/pathogenicity , Time Factors
7.
Tuberc Res Treat ; 2012: 170459, 2012.
Article in English | MEDLINE | ID: mdl-23029612

ABSTRACT

A retrospective observational study was performed to determine the sensitivity and limitation of PCR test for the detection of Mycobacterium tuberculosis and M. avium complex. We obtained clinical specimens collected from the respiratory tract, cultured M. tuberculosis or M. avium complex, and performed PCR analysis. A total of 299 samples (M. tuberculosis, 177; M. avium, 35; M. intracellulare, 87) were analyzed by COBAS TaqMan PCR from April 2007 to March 2011. The PCR positivity rates were 50-55%, 70-100%, 88-98%, and 100% in smear-negative, smear 1+, 2+, and 3+ groups, respectively. The PCR positivity of tuberculosis in smear 1+ was 80.6%, which was statistically significantly (P < 0.001) lower than that of smear 2+ (97.3%). From January 2005 to March 2007, we collected an additional 138 samples (M. tuberculosis, 74; M. avium, 21; M. intracellulare, 43), which were analyzed by COBAS Amplicor PCR. The PCR positivity rates obtained using COBAS TaqMan PCR and COBAS Amplicor PCR were not significantly different. The sensitivity of PCR test for mycobacteria is not sufficient in case of smear 1+. Careful consideration must be given to the interpretation of negative PCR test results in smear 1+, because smear-positive tuberculosis is the criterion for isolation.

SELECTION OF CITATIONS
SEARCH DETAIL